DERM
NASDAQ · Pharmaceuticals
Journey Medical Corp
$5.17
-0.24 (-4.44%)
Financial Highlights (FY 2026)
Revenue
61.62M
Net Income
-11,386,397
Gross Margin
66.2%
Profit Margin
-18.5%
Rev Growth
-5.7%
D/E Ratio
0.79
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 66.2% | 66.2% | 62.4% | 62.4% |
| Operating Margin | -13.2% | -11.9% | 16.9% | 16.2% |
| Profit Margin | -18.5% | -17.6% | 17.9% | 16.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 61.62M | 65.31M | 106.46M | 91.38M |
| Gross Profit | 40.77M | 43.22M | 66.48M | 57.06M |
| Operating Income | -8,139,651 | -7,765,195 | 17.94M | 14.85M |
| Net Income | -11,386,397 | -10,862,579 | 19.04M | 15.46M |
| Gross Margin | 66.2% | 66.2% | 62.4% | 62.4% |
| Operating Margin | -13.2% | -11.9% | 16.9% | 16.2% |
| Profit Margin | -18.5% | -17.6% | 17.9% | 16.9% |
| Rev Growth | -5.7% | -5.7% | +23.5% | +18.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 27.91M | 27.91M | 81.05M | 98.09M |
| Total Equity | 35.17M | 35.17M | 109.66M | 130.87M |
| D/E Ratio | 0.79 | 0.79 | 0.74 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -3,899,584 | -3,926,865 | 19.03M | 16.26M |
| Free Cash Flow | — | — | 11.82M | 11.85M |